Emergency department use by patients who received chimeric antigen receptor T cell infusion therapy.

ABSTRACT:

Background

Chimeric antigen receptor T cell infusion (CAR T) therapy has revolutionized the treatment of hematologic malignancies, but treatment-related toxicities are of concern. Understanding the timing and reasons for which patients present to the emergency department (ED) after CAR T therapy can assist with the early recognition and management of toxicities.

Methods

A retrospective observational cohort study was conducted for patients who had undergone CAR T therapy in the past 6 months and visited the ED of The University of Texas MD Anderson Cancer Center between 04/01/2018 and 08/01/2022. The timing of presentation after CAR T product infusion, patient characteristics, and outcomes of the ED visit were examined. Survival analyses were conducted using Cox proportional

SUBMITTER: Lipe DN 

PROVIDER: S-EPMC10064130 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature